We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
TOY | Toys R Us ANZ Ltd | 0.095 | 0.086 | 955.56% | 66,642 | 31 |
BP8 | BPH Global Ltd | 0.004 | 0.003 | 300.00% | 3,422,941 | 19 |
JATO | Jatcorp Limited | 0.004 | 0.003 | 300.00% | 414,355 | 6 |
FTL | Firetail Resources Ltd | 0.1125 | 0.0665 | 144.57% | 25,368,931 | 761 |
BEO | Beonic Ltd | 0.03 | 0.008 | 36.36% | 269,500 | 7 |
GCM | Green Critical Minerals Ltd | 0.004 | 0.001 | 33.33% | 608,675 | 3 |
VPR | Volt Power Group Limited | 0.002 | 0.0005 | 33.33% | 20,498,641 | 12 |
EUROB | European Lithium Limited | 0.004 | 0.001 | 33.33% | 372,000 | 3 |
OSX | Osteopore Limited | 0.07 | 0.017 | 32.08% | 34,608,080 | 1,131 |
MPP | Metro Performance Glass Limited | 0.083 | 0.017 | 25.76% | 94,812 | 2 |
SIX | Sprintex Ltd | 0.045 | 0.009 | 25.00% | 1,964,199 | 77 |
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, polymer chemistry, philosophy, psychology, sociology, and many other disciplines to form a comprehensive research institute based on various disciplines centered on consciousness.
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
VANCOUVER, BC, June 5, 2024 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk (PTT) over Cellular (PoC) handsets and accessories, today announced its partnership with JD Telecom, a premier telecom solutions provider of commercial-grade vehicle solutions and a strategic distribution partner for T-Mobile, to expand distribution of its SD7 handsets, VK7 Vehicle Kits and related components.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 71,144.20 | 66.87 | 0.09% | 1.4T | 3,561,374,178 |
ETH | Ethereum | 3,848.66 | -15.55 | -0.40% | 462.72B | 1,921,750,831 |
BNB | Binance Coin | 704.92 | 6.27 | 0.90% | 111.55B | 447,274,721 |
USDT | Tether USD | 0.99965 | -0.00036 | -0.04% | 97.8B | 229,325,304 |
SOL | Solana | 173.05 | -0.390 | -0.22% | 76.28B | 651,332,990 |
STETH | stETH | 3,828.61 | -34.05 | -0.88% | 37.59B | 5,232,370 |
XRP | Ripple | 0.5261 | 0.0005 | 0.10% | 28.73B | 226,017,174 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 859,809,183 |
TONCOIN | Wrapped TON Coin | 7.29 | 0.117851 | 1.64% | 25.46B | 125,710,872 |
DOGE | Dogecoin | 0.16329 | 0.00021 | 0.13% | 23.34B | 167,644,749 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions